ANIP ANI PHARMACEUTICALS INC
Price Chart
Executive Summary
ANI Pharmaceuticals held its 2026 Annual Meeting on May 21, 2026, where all seven director nominees were elected, Ernst & Young was ratified as auditor, say-on-pay was approved on an advisory basis, and stockholders approved the Amended and Restated 2022 Stock Incentive Plan. The plan adds up to 962,000 new shares to the existing reserve, bringing the total authorized pool to 8,222,000 shares. This is a routine governance filing with no material financial impact.
Actionable Insight
Routine annual meeting filing with no surprises. The increased share reserve for equity compensation is standard practice and does not signal any change in business outlook. Monitor next quarterly earnings for operational performance.
Key Facts
- Stockholders approved the Amended and Restated 2022 Stock Incentive Plan, increasing the share reserve by up to 962,000 shares to a total of 8,222,000 shares.
- All seven director nominees were elected with strong support (lowest 'for' vote was 14,063,620 for Renee P. Tannenbaum).
- Ernst & Young LLP was ratified as independent auditor for FY2026 with 16,874,103 votes in favor.
- Say-on-pay was approved on an advisory basis (13,819,988 for, 1,058,460 against).
- Stockholders voted for an annual frequency for future say-on-pay advisory votes.
- No officer departures, appointments, or material compensation changes were reported.
Financial Impact
No material financial impact. The stock plan amendment authorizes up to 962,000 additional shares, representing approximately 4.2% of the 22,750,198 common shares outstanding as of the record date.
Risk Factors
- Potential future dilution from equity grants under the expanded plan, though this is typical for a pharmaceutical company.
- Say-on-pay opposition of ~7% (1,058,460 against out of 14,895,825 votes cast) is modest and not a red flag.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000056 |
| Document: ani-20260521.htm | 0001023024-26-000056 |
| Document: 0001023024-26-000056-index-headers.html | 0001023024-26-000056 |
| Document: 0001023024-26-000056-index.html | 0001023024-26-000056 |
| Document: 0001023024-26-000056.txt | 0001023024-26-000056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 15, 2026
3d ago
|
Insider Cluster
| $83.00 $80.52 | ▼ −2.99% | ▼ −1.74% | $80.52 (−2.99%) |
|
Jun 11, 2026
8d ago
|
Insider Cluster
| $81.65 $81.68 | ▲ +0.04% | ▼ −0.50% | $80.52 (−1.38%) |
|
May 21, 2026
28d ago
|
8-K
| $82.72 $81.41 | ▼ −1.58% | ▼ −2.17% | $80.52 (−2.66%) |
|
May 13, 2026
5w ago
|
8-K
| $80.88 $79.58 | ▼ −1.61% | ▼ −2.38% | $80.52 (−0.45%) |
|
May 11, 2026
5w ago
|
Insider Cluster
| $78.71 $79.50 | ▲ +1.00% | ▲ +1.14% | $80.52 (+2.30%) |
|
May 8, 2026
5w ago
|
8-K
| $81.86 $78.71 | ▼ −3.85% | ▼ −4.08% | $80.52 (−1.64%) |
|
May 8, 2026
5w ago
|
Press Release
| $81.86 $78.71 | ▼ −3.85% | ▼ −4.08% | $80.52 (−1.64%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $78.64 $79.60 | ▲ +1.22% | ▲ +1.06% | $80.52 (+2.39%) |
|
Apr 8, 2026
10w ago
|
Press Release
| $79.01 $80.14 | ▲ +1.43% | ▲ +0.86% | $80.52 (+1.91%) |
|
Apr 7, 2026
10w ago
|
8-K
| $79.01 $80.14 | ▲ +1.43% | ▲ +0.86% | $80.52 (+1.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access